Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

174.75
-3.6100-2.02%
Post-market: 175.000.2500+0.14%19:30 EDT
Volume:1.96M
Turnover:345.81M
Market Cap:23.45B
PE:-49.88
High:180.91
Open:177.17
Low:173.96
Close:178.36
52wk High:183.51
52wk Low:60.45
Shares:134.20M
Float Shares:129.78M
Volume Ratio:1.13
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-105.22
PE(LYR):-52.63

Loading ...

Guardant Health price target raised to $200 from $190 at Guggenheim

TIPRANKS
·
Yesterday

S&P 500 Futures Drop in Premarket Trading; Moog, AngloGold Ashanti Lag

Dow Jones
·
Sep 28

Guardant Health (GH) Receives a Buy from Bernstein

TIPRANKS
·
Sep 26

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Dow Jones
·
Sep 24

Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300

Reuters
·
Sep 18

US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee

Reuters
·
Sep 17

Guardant Health on Track for Record High Close

Dow Jones
·
Sep 17

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
Sep 16

Movement Alert|Guardant Health Inc. Rises 5.31% in Regular Trading, Shield Blood Test Secures Major New Insurance Coverage Agreement

Market Focus
·
Sep 16

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Reuters
·
Sep 15

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS
·
Sep 15

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Dow Jones
·
Sep 08

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live
·
Sep 08

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live
·
Sep 08

Guardant Health initiated with a Buy at Rothschild & Co Redburn

TIPRANKS
·
Sep 08

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

TIPRANKS
·
Sep 05

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS
·
Sep 05

Guardant Health Price Target Maintained with a $195.00/Share by BTIG

Dow Jones
·
Sep 02